Over the course of the projected year, the continuous glucose monitoring market in India is anticipated to grow at a CAGR of more than 17%, with sales of over USD 100 million in the current year.
Every sixth person with diabetes in the world lives in India, which has the second-largest adult diabetes population worldwide. After recovering from COVID-19, people run the risk of getting diabetes. With over 32 million documented infections, India has the second-highest COVID-19 caseload in the world, after the US. Whether COVID-19 causes diabetes in patients with no prior history was a topic of debate among physicians worldwide. In India, 8–10% of patients with COVID-19 who had no prior history of diabetes still had high blood sugar levels months after they had recovered and were taking medication.
The population with Type-1 diabetes, which numbered more than 60 million people by the projection period, is predicted to drive the sensors segment's growth with a CAGR of over 17% over that time.
The sensor, which detects glucose levels in diabetics, is a small electrode. Through a tiny filament that is put under the skin, the sensors continuously monitor and record the body's glucose levels. The customers can receive the data from the sensors in only five seconds. The Free Style Libre Pro sensor (14 days of operation), Dexcom's G4 sensor (10 days of operation), Medtronic's Guardian sensor (7 days of operation), and the fluorescence sensor are taken into consideration in India's market for continuous glucose monitoring devices.
The market study is also being driven by the rising incidence of diabetes and obesity, increased awareness of diabetic care, rising healthcare costs, and technological improvements. Younger onset of diabetes is more likely in children and adolescents. In adults, diabetes affects 9% of people. Diabetes lowers life expectancy, lowers quality of life, and raises societal healthcare expenses. As a result, both the demand for and adoption rate of continuous glucose monitoring devices are rising. These elements are anticipated to drive the market under study.
Major Players: Abbott and Medtronic
Comments
Post a Comment